Tesla Launches New Model Y Variant in the US Starting at $41,990 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
WALTHAM, Mass., Aug. 14, 2017 -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of delisting and deregistering its securities under the Exchange Act.
The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities and filed a Form 25 on August 4, 2017 as part of the process.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Contact: Eric Collins 617-886-6045
